/PRNewswire/ Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") announced that the U.S. Food and Drug Administration (FDA) has accepted the.
An assessment of 16 randomized clinical trials suggests shorter antibiotic durations are as safe and effective as longer durations in children with community-acquired pneumonia.